Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

Impact of dose interruption on the efficacy of lenvatinib in a phase 3 study in patients with radioiodine-refractory differentiated thyroid cancer.

Tahara M, Brose MS, Wirth LJ, Suzuki T, Miyagishi H, Fujino K, Dutcus CE, Gianoukakis A.

Eur J Cancer. 2018 Nov 21;106:61-68. doi: 10.1016/j.ejca.2018.10.002. [Epub ahead of print]

2.

Management of treatment-related toxicities in advanced medullary thyroid cancer.

Brose MS, Bible KC, Chow LQM, Gilbert J, Grande C, Worden F, Haddad R.

Cancer Treat Rev. 2018 May;66:64-73. doi: 10.1016/j.ctrv.2018.04.007. Epub 2018 Apr 22. Review.

PMID:
29704768
3.

Precision Targeted Therapy with BLU-667 for RET-Driven Cancers.

Subbiah V, Gainor JF, Rahal R, Brubaker JD, Kim JL, Maynard M, Hu W, Cao Q, Sheets MP, Wilson D, Wilson KJ, DiPietro L, Fleming P, Palmer M, Hu MI, Wirth L, Brose MS, Ou SI, Taylor M, Garralda E, Miller S, Wolf B, Lengauer C, Guzi T, Evans EK.

Cancer Discov. 2018 Jul;8(7):836-849. doi: 10.1158/2159-8290.CD-18-0338. Epub 2018 Apr 15.

PMID:
29657135
4.

Treatment-emergent hypertension and efficacy in the phase 3 Study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT).

Wirth LJ, Tahara M, Robinson B, Francis S, Brose MS, Habra MA, Newbold K, Kiyota N, Dutcus CE, Mathias E, Guo M, Sherman SI, Schlumberger M.

Cancer. 2018 Jun 1;124(11):2365-2372. doi: 10.1002/cncr.31344. Epub 2018 Apr 14.

PMID:
29656442
5.

Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.

Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, Nathenson M, Doebele RC, Farago AF, Pappo AS, Turpin B, Dowlati A, Brose MS, Mascarenhas L, Federman N, Berlin J, El-Deiry WS, Baik C, Deeken J, Boni V, Nagasubramanian R, Taylor M, Rudzinski ER, Meric-Bernstam F, Sohal DPS, Ma PC, Raez LE, Hechtman JF, Benayed R, Ladanyi M, Tuch BB, Ebata K, Cruickshank S, Ku NC, Cox MC, Hawkins DS, Hong DS, Hyman DM.

N Engl J Med. 2018 Feb 22;378(8):731-739. doi: 10.1056/NEJMoa1714448.

6.

Novel concepts for initiating multitargeted kinase inhibitors in radioactive iodine refractory differentiated thyroid cancer.

Tuttle RM, Brose MS, Grande E, Kim SW, Tahara M, Sabra MM.

Best Pract Res Clin Endocrinol Metab. 2017 Jun;31(3):295-305. doi: 10.1016/j.beem.2017.04.014. Epub 2017 May 12. Review.

7.

Effect of Age on the Efficacy and Safety of Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer in the Phase III SELECT Trial.

Brose MS, Worden FP, Newbold KL, Guo M, Hurria A.

J Clin Oncol. 2017 Aug 10;35(23):2692-2699. doi: 10.1200/JCO.2016.71.6472. Epub 2017 Jun 14.

PMID:
28613956
8.

The Challenges of Clinical Research in Rare Cancers: Bevacizumab Use in Low-Grade Serous Ovarian and Primary Peritoneal Cancers.

Grande C, Visovsky C, Brose MS.

J Adv Pract Oncol. 2017 May-Jun;8(4):388-391. Epub 2017 May 1. Review.

9.

Timing of multikinase inhibitor initiation in differentiated thyroid cancer.

Brose MS, Smit J, Lin CC, Pitoia F, Fellous M, DeSanctis Y, Schlumberger M, Tori M, Sugitani I.

Endocr Relat Cancer. 2017 May;24(5):237-242. doi: 10.1530/ERC-17-0016. Epub 2017 Mar 7.

10.

Vemurafenib for BRAFV600E-positive metastatic papillary thyroid cancer - Authors' response.

Brose MS, Singh N.

Lancet Oncol. 2016 Nov;17(11):e469. doi: 10.1016/S1470-2045(16)30520-4. No abstract available.

PMID:
27819236
11.

Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer.

Sherman SI, Clary DO, Elisei R, Schlumberger MJ, Cohen EE, Schöffski P, Wirth LJ, Mangeshkar M, Aftab DT, Brose MS.

Cancer. 2016 Dec 15;122(24):3856-3864. doi: 10.1002/cncr.30252. Epub 2016 Aug 15.

12.

Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial.

Brose MS, Cabanillas ME, Cohen EE, Wirth LJ, Riehl T, Yue H, Sherman SI, Sherman EJ.

Lancet Oncol. 2016 Sep;17(9):1272-82. doi: 10.1016/S1470-2045(16)30166-8. Epub 2016 Jul 23.

13.

Best Use of the Tyrosine Kinase Inhibitors in Progressive Differentiated Thyroid Cancer: Discussion.

Tuttle RM, Brose MS.

Clin Adv Hematol Oncol. 2016 May;14(5 Suppl 9):12-3. No abstract available.

PMID:
27168343
14.

Sequencing of Tyrosine Kinase Inhibitors in Progressive Differentiated Thyroid Cancer.

Brose MS.

Clin Adv Hematol Oncol. 2016 May;14(5 Suppl 9):7-12. Review. No abstract available.

PMID:
27168342
15.

pAKT Expression and Response to Sorafenib in Differentiated Thyroid Cancer.

Yarchoan M, Ma C, Troxel AB, Stopenski SJ, Tang W, Cohen AB, Pappas-Paxinos M, Johnson BA 3rd, Chen EY, Feldman MD, Brose MS.

Horm Cancer. 2016 Jun;7(3):188-95. doi: 10.1007/s12672-016-0253-6. Epub 2016 Mar 18.

PMID:
26994002
16.

STK11 Mutation Identified in Thyroid Carcinoma.

Wei S, LiVolsi VA, Brose MS, Montone KT, Morrissette JJ, Baloch ZW.

Endocr Pathol. 2016 Mar;27(1):65-9. doi: 10.1007/s12022-015-9411-6.

PMID:
26662608
17.

Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer.

Worden F, Fassnacht M, Shi Y, Hadjieva T, Bonichon F, Gao M, Fugazzola L, Ando Y, Hasegawa Y, Park DJ, Shong YK, Smit JW, Chung J, Kappeler C, Meinhardt G, Schlumberger M, Brose MS.

Endocr Relat Cancer. 2015 Dec;22(6):877-87. doi: 10.1530/ERC-15-0252.

18.

The Evolving Treatment Landscape for Metastatic Differentiated Thyroid Cancer.

Grande C, Brose MS.

J Adv Pract Oncol. 2014 Nov-Dec;5(6):461-5. Review. No abstract available.

19.

Reply to C. Bal et al and M. Xing.

Yarchoan M, LiVolsi VA, Brose MS.

J Clin Oncol. 2015 Aug 1;33(22):2483. doi: 10.1200/JCO.2015.61.4859. Epub 2015 Jun 29. No abstract available.

PMID:
26124481
20.

Sorafenib for patients with differentiated thyroid cancer--authors' reply.

Brose MS, Schlumberger M, Peña C, Kappeler C.

Lancet. 2015 Jan 17;385(9964):228-9. doi: 10.1016/S0140-6736(15)60056-3. No abstract available.

PMID:
25706706
21.

Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.

Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, Habra MA, Newbold K, Shah MH, Hoff AO, Gianoukakis AG, Kiyota N, Taylor MH, Kim SB, Krzyzanowska MK, Dutcus CE, de las Heras B, Zhu J, Sherman SI.

N Engl J Med. 2015 Feb 12;372(7):621-30. doi: 10.1056/NEJMoa1406470.

PMID:
25671254
22.

Clinical cancer advances 2015: Annual report on progress against cancer from the American Society of Clinical Oncology.

Masters GA, Krilov L, Bailey HH, Brose MS, Burstein H, Diller LR, Dizon DS, Fine HA, Kalemkerian GP, Moasser M, Neuss MN, O'Day SJ, Odenike O, Ryan CJ, Schilsky RL, Schwartz GK, Venook AP, Wong SL, Patel JD.

J Clin Oncol. 2015 Mar 1;33(7):786-809. doi: 10.1200/JCO.2014.59.9746. Epub 2015 Jan 20. Review. No abstract available.

PMID:
25605863
23.

BRAF mutation and thyroid cancer recurrence.

Yarchoan M, LiVolsi VA, Brose MS.

J Clin Oncol. 2015 Jan 1;33(1):7-8. doi: 10.1200/JCO.2014.59.3657. Epub 2014 Nov 24. No abstract available.

PMID:
25422487
24.

A phase I study of cabozantinib (XL184) in patients with differentiated thyroid cancer.

Cabanillas ME, Brose MS, Holland J, Ferguson KC, Sherman SI.

Thyroid. 2014 Oct;24(10):1508-14. doi: 10.1089/thy.2014.0125. Epub 2014 Aug 27.

25.

Second-line treatment for advanced thyroid cancer: an indication in need of randomized clinical trials.

Cohen AB, Brose MS.

J Clin Endocrinol Metab. 2014 Jun;99(6):1995-7. doi: 10.1210/jc.2014-2236. No abstract available.

PMID:
24893137
26.

Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial.

Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, de la Fouchardiere C, Pacini F, Paschke R, Shong YK, Sherman SI, Smit JW, Chung J, Kappeler C, Peña C, Molnár I, Schlumberger MJ; DECISION investigators.

Lancet. 2014 Jul 26;384(9940):319-28. doi: 10.1016/S0140-6736(14)60421-9. Epub 2014 Apr 24.

27.

Management of sorafenib-related adverse events: a clinician's perspective.

Brose MS, Frenette CT, Keefe SM, Stein SM.

Semin Oncol. 2014 Feb;41 Suppl 2:S1-S16. doi: 10.1053/j.seminoncol.2014.01.001. Epub 2014 Jan 9.

28.

Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology.

Patel JD, Krilov L, Adams S, Aghajanian C, Basch E, Brose MS, Carroll WL, de Lima M, Gilbert MR, Kris MG, Marshall JL, Masters GA, O'Day SJ, Polite B, Schwartz GK, Sharma S, Thompson I, Vogelzang NJ, Roth BJ.

J Clin Oncol. 2014 Jan 10;32(2):129-60. doi: 10.1200/JCO.2013.53.7076. Epub 2013 Dec 10.

PMID:
24327669
29.

Cabozantinib in progressive medullary thyroid cancer.

Elisei R, Schlumberger MJ, Müller SP, Schöffski P, Brose MS, Shah MH, Licitra L, Jarzab B, Medvedev V, Kreissl MC, Niederle B, Cohen EE, Wirth LJ, Ali H, Hessel C, Yaron Y, Ball D, Nelkin B, Sherman SI.

J Clin Oncol. 2013 Oct 10;31(29):3639-46. doi: 10.1200/JCO.2012.48.4659. Epub 2013 Sep 3. Erratum in: J Clin Oncol. 2014 Jun 10;32(17):1864.

30.

Efatutazone, an oral PPAR-γ agonist, in combination with paclitaxel in anaplastic thyroid cancer: results of a multicenter phase 1 trial.

Smallridge RC, Copland JA, Brose MS, Wadsworth JT, Houvras Y, Menefee ME, Bible KC, Shah MH, Gramza AW, Klopper JP, Marlow LA, Heckman MG, Von Roemeling R.

J Clin Endocrinol Metab. 2013 Jun;98(6):2392-400. doi: 10.1210/jc.2013-1106. Epub 2013 Apr 15.

31.

Physician and stakeholder perceptions of conflict of interest policies in oncology.

Lockhart AC, Brose MS, Kim ES, Johnson DH, Peppercorn JM, Michels DL, Storm CD, Schuchter LM, Rathmell WK.

J Clin Oncol. 2013 May 1;31(13):1677-82. doi: 10.1200/JCO.2012.47.5475. Epub 2013 Mar 25.

32.

Clinical cancer advances 2012: annual report on progress against cancer from the american society of clinical oncology.

Roth BJ, Krilov L, Adams S, Aghajanian CA, Bach P, Braiteh F, Brose MS, Ellis LM, Erba H, George DJ, Gilbert MR, Jacobson JO, Larsen EC, Lichtman SM, Partridge AH, Patel JD, Quinn DI, Robison LL, von Roenn JH, Samlowski W, Schwartz GK, Vogelzang NJ.

J Clin Oncol. 2013 Jan 1;31(1):131-61. doi: 10.1200/JCO.2012.47.1938. Epub 2012 Dec 3. No abstract available. Erratum in: J Clin Oncol. 2013 Jun 1;31(16):2063.

PMID:
23213095
33.

Regional approaches to the management of patients with advanced, radioactive iodine-refractory differentiated thyroid carcinoma.

Brose MS, Smit J, Capdevila J, Elisei R, Nutting C, Pitoia F, Robinson B, Schlumberger M, Shong YK, Takami H.

Expert Rev Anticancer Ther. 2012 Sep;12(9):1137-47. doi: 10.1586/era.12.96.

PMID:
23098114
34.

RAP1GAP inhibits cytoskeletal remodeling and motility in thyroid cancer cells.

Dong X, Tang W, Stopenski S, Brose MS, Korch C, Meinkoth JL.

Endocr Relat Cancer. 2012 Jul 22;19(4):575-88. doi: 10.1530/ERC-12-0086. Print 2012 Aug.

35.

Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study.

Chu EY, Wanat KA, Miller CJ, Amaravadi RK, Fecher LA, Brose MS, McGettigan S, Giles LR, Schuchter LM, Seykora JT, Rosenbach M.

J Am Acad Dermatol. 2012 Dec;67(6):1265-72. doi: 10.1016/j.jaad.2012.04.008. Epub 2012 May 18.

36.

In search of a real "targeted" therapy for thyroid cancer.

Brose MS.

Clin Cancer Res. 2012 Apr 1;18(7):1827-9. doi: 10.1158/1078-0432.CCR-12-0153. Epub 2012 Mar 26.

37.
38.

Targeted inhibition of CD133+ cells in oral cancer cell lines.

Damek-Poprawa M, Volgina A, Korostoff J, Sollecito TP, Brose MS, O'Malley BW Jr, Akintoye SO, DiRienzo JM.

J Dent Res. 2011 May;90(5):638-45. doi: 10.1177/0022034510393511. Epub 2011 Jan 10.

39.

The RET/PTC3 oncogene activates classical NF-κB by stabilizing NIK.

Neely RJ, Brose MS, Gray CM, McCorkell KA, Leibowitz JM, Ma C, Rothstein JL, May MJ.

Oncogene. 2011 Jan 6;30(1):87-96. doi: 10.1038/onc.2010.396. Epub 2010 Sep 6.

40.

Downregulation of Rap1GAP in human tumor cells alters cell/matrix and cell/cell adhesion.

Tsygankova OM, Ma C, Tang W, Korch C, Feldman MD, Lv Y, Brose MS, Meinkoth JL.

Mol Cell Biol. 2010 Jul;30(13):3262-74. doi: 10.1128/MCB.01345-09. Epub 2010 May 3.

41.

Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas.

Dougherty MJ, Santi M, Brose MS, Ma C, Resnick AC, Sievert AJ, Storm PB, Biegel JA.

Neuro Oncol. 2010 Jul;12(7):621-30. doi: 10.1093/neuonc/noq007. Epub 2010 Feb 14.

42.

Targeting vascular endothelial growth factor receptor in thyroid cancer: the intracellular and extracellular implications.

Keefe SM, Cohen MA, Brose MS.

Clin Cancer Res. 2010 Feb 1;16(3):778-83. doi: 10.1158/1078-0432.CCR-08-2743. Epub 2010 Jan 26. Review.

43.

Sorafenib-Related Hand-Foot Skin Reaction Improves, Not Worsens, with Continued Treatment.

Flaherty KT, Brose MS.

Clin Cancer Res. 2009 Dec 15;15(24):7749. No abstract available.

44.

SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas.

Bass AJ, Watanabe H, Mermel CH, Yu S, Perner S, Verhaak RG, Kim SY, Wardwell L, Tamayo P, Gat-Viks I, Ramos AH, Woo MS, Weir BA, Getz G, Beroukhim R, O'Kelly M, Dutt A, Rozenblatt-Rosen O, Dziunycz P, Komisarof J, Chirieac LR, Lafargue CJ, Scheble V, Wilbertz T, Ma C, Rao S, Nakagawa H, Stairs DB, Lin L, Giordano TJ, Wagner P, Minna JD, Gazdar AF, Zhu CQ, Brose MS, Cecconello I, Ribeiro U Jr, Marie SK, Dahl O, Shivdasani RA, Tsao MS, Rubin MA, Wong KK, Regev A, Hahn WC, Beer DG, Rustgi AK, Meyerson M.

Nat Genet. 2009 Nov;41(11):1238-42. doi: 10.1038/ng.465. Epub 2009 Oct 4.

45.

Thyroid cancer update: dramatic changes in the treatment of a rare disease.

Brose MS.

Oncology (Williston Park). 2009 Aug;23(9):778, 781. No abstract available.

46.

Characterization CSMD1 in a large set of primary lung, head and neck, breast and skin cancer tissues.

Ma C, Quesnelle KM, Sparano A, Rao S, Park MS, Cohen MA, Wang Y, Samanta M, Kumar MS, Aziz MU, Naylor TL, Weber BL, Fakharzadeh SS, Weinstein GS, Vachani A, Feldman MD, Brose MS.

Cancer Biol Ther. 2009 May;8(10):907-16. Epub 2009 May 9.

PMID:
19276661
47.

Loss of Rap1GAP in papillary thyroid cancer.

Nellore A, Paziana K, Ma C, Tsygankova OM, Wang Y, Puttaswamy K, Iqbal AU, Franks SR, Lv Y, Troxel AB, Feldman MD, Meinkoth JL, Brose MS.

J Clin Endocrinol Metab. 2009 Mar;94(3):1026-32. doi: 10.1210/jc.2008-1042. Epub 2008 Dec 9.

48.

A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel.

Flaherty KT, Schiller J, Schuchter LM, Liu G, Tuveson DA, Redlinger M, Lathia C, Xia C, Petrenciuc O, Hingorani SR, Jacobetz MA, Van Belle PA, Elder D, Brose MS, Weber BL, Albertini MR, O'Dwyer PJ.

Clin Cancer Res. 2008 Aug 1;14(15):4836-42. doi: 10.1158/1078-0432.CCR-07-4123.

49.

Phase II trial of sorafenib in advanced thyroid cancer.

Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K, Mandel SJ, Flaherty KT, Loevner LA, O'Dwyer PJ, Brose MS.

J Clin Oncol. 2008 Oct 10;26(29):4714-9. doi: 10.1200/JCO.2008.16.3279. Epub 2008 Jun 9.

50.

Application of a BRAF pyrosequencing assay for mutation detection and copy number analysis in malignant melanoma.

Spittle C, Ward MR, Nathanson KL, Gimotty PA, Rappaport E, Brose MS, Medina A, Letrero R, Herlyn M, Edwards RH.

J Mol Diagn. 2007 Sep;9(4):464-71. Epub 2007 Aug 9.

Supplemental Content

Loading ...
Support Center